In summary, our data showed that naringin inhibits the malignant phenotype of osteosarcoma cells by inhibiting the expression of Zeb1 and Zeb1-associated proteins such as Cyclin D1 and MMP2. Here, ZEB1 is linked to osteosarcoma.